ASLAN and Hyundai Partner on Cancer Drug in Korea

ASLAN Pharma, a Singapore-based cancer company, will collaborate with Hyundai Pharm Co. to develop and commercialize ASLAN001 for cholangiocarcinoma (CCA) in South Korea. ASLAN001 is a small molecule pan-HER inhibitor that targets CCA, an aggressive form of bile duct cancer with no approved therapy. Hyandai will also have first negotiation rights on ASLAN001 as a treatment for gastric and breast cancer in South Korea. The two companies will collaborate on clinical trials for the molecule, and ASLAN will retain co-marketing rights in South Korea. More details.... Share this with colleagues: // //